Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Extended Access of Momelotinib for Subjects With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)

NCT03441113 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT03441113
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03441113 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Extended Access of Momelotinib for Subjects With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)
Lead sponsor
GlaxoSmithKline
Phase
Phase 2
Overall status
Active, not recruiting
Start date
May 3, 2018
Completion date
December 11, 2026
Enrollment
237 (actual)
Sites
112

Conditions

As the registry lists them; a condition with its own page is linked.

neoplasms, post-essential thrombocythemia myelofibrosis (post-et mf), post-polycythemia vera myelofibrosis (post-pv mf), primary myelofibrosis, primary myelofibrosis (pmf)